Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 13/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 9/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 9/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
| ▸ | HTR1B | P28222 | 2/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 10/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 10/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986530 | 0.76 | ADRA1A (0.50) | ADRA1AADRA2AADRA2CTAAR1ADRA2B | |
| SCHEMBL2561416 | 0.76 | HTR1D (0.50) | ADRA1AADRA2AADRA2CTAAR1ADRA2B | |
| SCHEMBL4992395 | 0.76 | HTR1D (0.50) | ADRA1AADRA2AADRA2CTAAR1ADRA2B | |
| SCHEMBL13752307 | 0.76 | HTR1D (0.50) | ADRA1AADRA2AADRA2CTAAR1MAPK1 | |
| SCHEMBL4983426 | 0.76 | ADRA1A (0.45) | ADRA1AADRA2AADRA2CTAAR1ADRA2B | |
| SCHEMBL14092049 | 0.75 | HTR1D (0.49) | ADRA1AADRA2AADRA2CTAAR1ADRA2B | |
| Hydrochloric Acid SCHEMBL3726850 | 0.75 | HTR1D (0.49) | ADRA1AADRA2AADRA2CTAAR1MAPK1 | |
| SCHEMBL12304316 | 0.75 | HTR1D (0.41) | ADRA1AADRA2AADRA2CTAAR1MAPK1 | |
| SCHEMBL2387364 | 0.75 | ADRA1A (0.45) | ADRA1AADRA2AADRA2CTAAR1ADRA2B | |
| SCHEMBL4993116 | 0.75 | HTR1D (0.39) | ADRA1AADRA2AADRA2CTAAR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407980-B2 | Imidazolinylmethyl aralkylsulfonamides | ROCHE PALO ALTO LLC (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407980-B2 | Imidazolinylmethyl aralkylsulfonamides | ROCHE PALO ALTO LLC (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407980-B2 | Imidazolinylmethyl aralkylsulfonamides | ROCHE PALO ALTO LLC (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1501817-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20040214875-A1 | Imidazolinylmethyl aralkylsulfonamides | ROCHE PALO ALTO LLC | 2004-10-28 | — | — | US | disclosed |
| US-6756395-B2 | CYCLIZATION OF N-(4-CYANOMETHYLPHENYL)METHANESULFONAMIDES WITH ETHYLENEDIAMINE TO FORM N-(4-IMIDAZOL-2-YLMETHYL)-PHENYL) -METHANESULFONAMIDES; INCONTINENCE, SEXUAL DYSFUNCTION, NASAL CONGESTION, AND CNS DISORDERS; ALPHA 1 ADRENERGIC AGONISTS | ROCHE PALO ALTO LLC | 2004-06-29 | — | — | US | disclosed |
| US-20030229130-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | ROCHE PALO ALTO LLC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003091236-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214875-A1 | Imidazolinylmethyl aralkylsulfonamides | RPS6KA1, RPS6KB1, RPS6KA6 | ADRA1A 2525/4885ADRA2A 3909/4885ADRA2C 3707/4885 |
| US-20030229130-A1 | IMIDAZOLINYLMETHYL ARALKYLSULFONAMIDES | RPS6KA1, RPS6KB1, RPS6KA6 | ADRA1A 2525/4885ADRA2A 3909/4885ADRA2C 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.